¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time and motion studies"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£, È£ÈíÁßÁö½Ã°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • thrombin time
    Æ®·Òºó½Ã°£
  • transit time
    ÀüÀ̽ð£, Åë°ú½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • real time ultrasonography
    ½Ç½ÃÃÊÀ½ÆÄÃÔ¿µ¼ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • dilatation and curettage
    ÀڱøñÈ®Àå±Ü¾î³¿¼ú, °æ°üÈ®ÀåÀÚ±Ã¼ÒÆÄ¼ú
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • law of weights and measures
    °è·®¹ý
  • trial-and-error learning
    ½ÃÇàÂø¿ÀÇнÀ
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
  • glycerin and potash solution
    ±Û¸®¼¼¸° Ä®·ý¾×.
  • gray matter (nuclei and columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • hand and foot disease
    ¼ö Á· Áúȯ£¨â¢ðëòðü´£©£¬¼Õ ¹ß º´, ¼ö Á· º´ (â¢ðëÜ»).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ)
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
  • hereditary motor and sensory neuropathy
    À¯Àü¼º¿îµ¿ °¨°¢½Å°æº´Áõ
  • incision and drainage
    Àý°³¹è³ó(ü°³¹è³ó).
  • personality, anxious and fearful
    ºÒ¾È°øÆ÷¼º ÀΰÝ
  • pharmacy and therapeutic committee
    ¾à»çÀÇ·áÀ§¿øÈ¸(ËâË×ËöËíËôËôÌ·) º´¿ø(ËÓ Ëô)ÀÇ .
  • pneumocyte, types i and ii
    ÆóÆ÷¼¼Æ÷(øËøàá¬øà), IÇü°ú IIÇü
  • porokeratotoic eccrine ostial and dermal duct nevus
    ÇѰø°¢È­Áõ¼º ¿¡Å©¸°±¸¸Û ¹× ÁøÇǰü¸ð¹Ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • muscular motion
    ±Ù ¿îµ¿(ÐÉê¡ÔÑ).
  • nonuniform motion
    ºñ±ÕÀÏ ¿îµ¿
  • on motion
    ¿îµ¿½Ã(ËôËÄËà)ÀÇ.
  • paradoxical motion
    ¿ªÇ༺ ¿îµ¿.
  • paradoxical motion
    ¿ªÇ༺ ¿îµ¿.
  • perpetual motion
    ¿µ±¸¿îµ¿(çµÎùê¡ÔÑ).
  • planetary motion
    Ç༺¿îµ¿.
  • range of joint motion
    °üÀý ¿îµ¿ ¹üÀ§(μï½ê¡ÔÑÛôêÌ).
  • range of motion
    ¿îµ¿¹üÀ§(ê¡ÔÑÛôêÌ), ¿îµ¿ÇѰè(ê¡ÔÑùÚÍ£).
  • relative motion
    »ó´ë¿îµ¿(ßÓÓßê¡ÔÑ).
  • rephasing gradient motion
    ÀçÀ§»ó °æ»ç ¿îµ¿
  • retrograde motion
    ¿ªÇ༺ ¿îµ¿(æ½ú¼àõê¡ÔÑ).
  • retrograde motion
    ¿ªÇà¿îµ¿.
  • scissors motion
    °¡À§¿òÁ÷ÀÓ
  • sector scan motion
    ºÎä²Ã ½ºÄµ ¿îµ¿
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • resolving time
    "ºÐ¸®½Ã°£, ÇØ»ó½Ã°£"
  • retention time
    ¸Ó¹«¸§ ½Ã°£
  • rotational relaxation time
    ȸÀü À̿Ͻð£(üÞï®ì¬èÐãÁÊà)
  • thermal death time
    ¿­»ç½Ã°£ (æðÞÝãÁÊà)
  • time constant
    ½Ã°£»ó¼ö (ãÁÊàßÈâ¦)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • transient time
    °úµµ±â ½Ã°£(ΦԤѢãÁÊà)
  • turnover time
    Àüȯ½Ã°£(ï®üµãÁÊà)
  • zero time binding DNA
    ¿µ½Ã(çÍãÁ) °áÇÕ(Ì¿ùê) DNA
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • spin echo intravoxel incoherent motion imaging
    ½ºÇÉ¿¡ÄÚÈ­Àû¼Ò³» ºñ°áÁý¿îµ¿¿µ»ó¼ú
  • vermicular motion
    ¿¬µ¿
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • doubling time
    ¹è°¡½Ã°£
  • echo time [=TE]
    ¿¡Äڽð£
  • elapsed time
    °æ°ú½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Á¶ ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • half-life; half-time
    ¹Ý°¨±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PST pancreatic suppression test; paroxysmal supraventricular tachycardia; penicillin, streptomycin, and ...
CRT cadaveric renal transplant; cardiac resuscitation team; cathode-ray tube; certified; Certified Recor...
ET educational therapy; effective temperature; ejection time; embryo transfer; endothelin; endotoxin; e...
MRT magnetic resonance tomography; maximum relaxation time; median range score; median reaction time; me...
RT radiologic technologist; radiotelemetry; radiotherapy; radium therapy; rapid tranquilization; reacti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
35S Studies using
35S Studies with
TE time , expiratory time
AM Apparent motion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • contact time
    Á¢ÃË ½Ã°£
  • correlation time
    »ó°ü ½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • echo time
    ¿¡ÄÚ ½Ã°£
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
  • fast time constant circuit
    °í¼Ó ½Ã°£ °íÁ¤ ȸ·Î
  • first-time dental patient
    óÀ½ ³»¿øÇÑ È¯ÀÚ
  • hardening time
    °æÈ­ ½Ã°£
    Ä¡°ú¿ë ÀλóÀç ¶Ç´Â ¼®°í°¡ µüµüÇÏ°Ô ±»´Âµ¥ °É¸®´Â ½Ã°£.
  • inversion time
    ¿ªÀü ½Ã°£
  • left ventricular ejection time
    Á ½É½Ç ±¸Ç÷ ±â°£
  • mixing time
    ±³¹Ý ½Ã°£, È¥ÇÕ ½Ã°£
    µÎ °¡Áö ÀÌ»óÀÇ Àç·á¸¦ È¥ÇÕÇÒ ¶§ ¼Ò¿äµÇ°Å³ª ÁöÄÑ¾ß ÇÏ´Â ½Ã°£À¸·Î, Ä¡°ú ¿µ¿ª¿¡¼­´Â ¼®°í Àç·á, ½Ã¸àÆ®, ¼öÁö, ÀλóÀç, ¸Å¸ôÀç µî¿¡¼­ ÁؼöµÇ¾î¾ß ÇÒ ½Ã°£. Àç·áÀÇ ¹°¸®Àû ¼ºÁú¿¡ ¿µÇâÀ» ÁØ´Ù.
  • operative time
    ¼ö¼ú ½Ã°£
  • partial prothrombin time
    ºÎºÐ ÇÁ·ÎÆ®·Òºó ½Ã°£
  • persistence time
    Áö¼Ó ½Ã°£
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
epidemiologic studies Studies designed to examine associations, commonly, hypothesised causal relations. They are usually concerned with identifying or measuring the effects of risk factors or exposures. The common types of analytic study are case-control studies, cohort studies, and cross-sectional studies.
(12 Dec 1998)
evaluation studies Studies determining the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. For drugs and devices, clinical trials, drug evaluation, and drug screening are available.
(12 Dec 1998)
twin studies Methods of detecting genetic aetiology in human traits. The basic premise of twin studies is that monozygotic twins, being formed by the division of a single fertilised ovum, carry identical genes, while dizygotic twins, being formed by the fertilization of two ova by two different spermatozoa, are genetically no more similar than two siblings born after separate pregnancies.
(12 Dec 1998)
feasibility studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
(12 Dec 1998)
follow-up studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
(12 Dec 1998)
longitudinal studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
(12 Dec 1998)
activated clotting time The most common test used for coagulation time in cardiovascular surgery.
(05 Mar 2000)
activated partial thromboplastin time The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system.
(05 Mar 2000)
A-H conduction time Forward conduction of the cardiac impulse from atria to ventricles via the A-V node or any bypass tract, represented in the electrocardiogram by the P-R interval. P-H conduction time is from the onset of the P wave to the first high frequency component of the His bundle electrogram (normally 119 ± 38 msec); A-H conduction time is from the onset of the first high frequency component of the atrial electrogram to the first high frequency component of the His bundle electrogram (normally 92 ± 38 msec); P-A conduction time is from the onset of the P wave to the onset of the atrial electrogram (normally 27 ± 18 msec).
(05 Mar 2000)
association time Time elasping between a stimulus and the verbalised response to it.
(05 Mar 2000)
biologic time The concept that our appreciation of time varies with age and is governed by the neural organization of the individual; it obeys a logarithmic rather than an arithmetic law.
(05 Mar 2000)
bleeding time <haematology> A test which measures the time it takes for small blood vessels to close off and bleeding to stop. Abnormal results can be seen in those with congenital or acquired platelet function disorders or thrombocytopenia.
(27 Sep 1997)
blood circulation time Determination of the shortest time interval between the injection of a substance in the vein and its arrival at some distant site in sufficient concentration to produce a recognizable end result. It represents approximately the inverse of the average velocity of blood flow between two points.
(12 Dec 1998)
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • now and again
    À̵û±Ý
  • now and then
    ¶§¶§·Î (every ... ... ....)
  • off and on
    ºÒ±ÔÄ¢ÇϰÔ
  • on and on
    °è¼ÓÇÏ¿©
  • once and for all
    ¸¶Áö¸·À¸·Î
  • one and all
    ÇÑ »ç¶÷ ºüÁü¾øÀÌ
  • over and over again
    µÇÇ®ÀÌÇØ¼­
  • safe and sound
    ¹«»çÈ÷
  • touch-and-go
    ¸÷½Ã ºÒ¾ÈÇÑ
  • up-and-down
    ¿À¸£³»¸®´Â
  • Box and Cox
    µ¿½Ã¿¡´Â ¾È ³ªÅ¸³ª´Â µÎ »ç¶÷;ÇÑ ¿ªÇÒÀ» ±³´ë·Î ÇÏ´Â µÎ »ç¶÷
  • C and (&) W
    country-and-western
  • Damon and Pythias
    ´Ù¸Õ°ú ÇÇÆ¼¾Æ½º(¿¾ ±Û½º¿¡¼­ ¸ñ¼ûÀ» °É°í ¸Í¼¼¸¦ ÁöŲ µÎ Ä£±¸);µÑµµ ¾ø´Â Ä£±¸;ÀýÄ£ÇÑ Ä£±¸;¸·¿ªÇÑ ¹þ ', '
  • Daphnis and Chloe
    ´ÙÇÁ´Ï½º¿Í Ŭ·Î¿¡(2-3¼¼±â°æ ±×¸®½ºÀÇ ¸ñ°¡ÀûÀÎ À̾߱⠼ÓÀÇ ¼øÁøÇÑ ¿¬Àεé)
  • Darby and Joan
    (¹Î¿äÁßÀÇ ³ëºÎºÎ¿¡¼­);ÀÇÁÁÀº ´ÄÀº ºÎºÎ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á